Pharmaceutical Industry Litigation Funding: What You Should Know

Jamison Lynch and Dr. Lauren Rabinovic of GLS Capital explore the fundamentals, evaluation criteria, and benefits of litigation funding in the pharmaceutical industry, looking at the recent Hatch-Waxman litigation as an example of using capital as a strategic tool for defendants, and consider the various challenges faced in bringing litigation in the pharmaceutical sector, the differences in approach to litigation in the pharmaceutical industry compared to other industries, and the impact of funding on the industry.

Read more.